{
    "clinical_study": {
        "@rank": "117526", 
        "acronym": "PK/PD", 
        "arm_group": [
            {
                "arm_group_label": "Quercetin", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of quercetin with or without ascorbic acid"
            }, 
            {
                "arm_group_label": "isoquercetin", 
                "arm_group_type": "Active Comparator", 
                "description": "Single dose of isoquercetin with or without ascorbic acid"
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of this study is to evaluate how much quercetin or isoquercetin is absorbed after a\n      single dose and evaluate for pharmacokinetic inhibition of protein disulfide isomerase.\n      Pharmacodynamic studies will also be performed in an additional cohort of 10 patients with\n      evidence of antiphospholipid antibodies"
        }, 
        "brief_title": "Quercetin PK/PD Study in Healthy Adults and Patients With Elevated Anti-phospholipid Antibodies", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "To compare the absorption and activity of quercetin or isoquercetin with or without ascorbic\n      acid in healthy adults. Oral chews containing quercetin (500mg) or isoquercetin(500 mg\n      total) with or without ascorbic acid will be given. Pharmacokinetic parameters (AUC, Cmax,\n      Tmax, elimination half-life) will be determined over 24 hours (8 time points).\n      Pharmacodynamic inhibition of protein disulfide isomerase activity will also be assessed.\n\n      In addition to healthy subjects, a cohort of 10 individuals with antiphospholipid antibodies\n      will participate. These participants will receive isoquercetin 1000 mg and have\n      pharmacodynamics studies performed at time 0 and 4 hours.\n\n      All study drugs will be provided by Quercegen Pharma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Subject is willing to participate and provide informed consent\n\n          -  Subject is considered reliable and capable of adhering to the protocol per the\n             judgment of the Investigator\n\n          -  Subjects in group D must exhibit good organ reserves (within prior 4 weeks) defined\n             as:\n\n               1. Estimated GFR >35 (formula),\n\n               2. Platelet count >100 K/uL,\n\n               3. Hemoglobin >10.5 grams/dL\n\n               4. Total bilirubin <2.0 mg/dL\n\n          -  Ages 18-60 years old\n\n          -  Normal weight as determined by body mass index (BMI) between 18 and 30 kg/m2\n\n          -  For cohort D (antiphospholipid antibodies) a. Subjects in group D must have at least\n             one positive antiphospholipid antibody within the last 8 weeks and/or previous\n             confirmed antibodies (2 or more occasions at least 12 weeks apart) : i. Positive\n             lupus anticoagulant ii. anticardiolipin antibody IgM or IgG (>40U GPL) iii. anti-\u03b22\n             Glycoprotein1 antibody titer (>99th percentile)\n\n        Exclusion Criteria\n\n          -  Pregnant. If female of child-bearing age, negative urinary pregnancy test prior to\n             dosing of quercetin or isoquercetin\n\n          -  No history of malabsorptive gastrointestinal disorder\n\n          -  Currently taking aspirin, NSAIDS, warfarin, low-molecular weight heparin or other\n             anticoagulants (such as direct thrombin inhibitors or factor X inhibitors)\n\n             a. Note: Study subjects taking aspirin or NSAIDS, if treating physician concurs, are\n             permitted to enroll if plan to hold for aspirin 10 days or NSAIDS 24 hours prior to\n             dosing of quercetin/isoquercetin\n\n          -  Prescribed niacin for hyperlipidemia\n\n          -  Known HIV\n\n          -  Splenectomized\n\n          -  History of sensitivity or intolerance to flavonoids, niacin or ascorbic acid\n\n          -  May not have uncontrolled intercurrent illness including, but not limited to ongoing\n             or active infection, hepatitis, symptomatic congestive heart failure, unstable angina\n             pectoris or cardiac arrhythmia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01722669", 
            "org_study_id": "2012P-000022"
        }, 
        "intervention": {
            "arm_group_label": [
                "Quercetin", 
                "isoquercetin"
            ], 
            "intervention_name": "isoquercetin or quercetin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Antiphospholipid", 
                "Quercetin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "quercetin", 
            "isoquercetin", 
            "pharmacokinetic", 
            "pharmacodynamic"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02215"
                }, 
                "name": "Beth Israel Deaconess Medical Center"
            }, 
            "investigator": {
                "last_name": "Jeffrey Zwicker, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacokinetic and Pharmacodynamic Study of Oral Quercetin and Isoquercetin in Healthy Adults and Patients With Elevated Anti-phospholipid Antibodies", 
        "overall_contact": {
            "last_name": "Jeffrey Zwicker, MD", 
            "phone": "617-667-9299"
        }, 
        "overall_official": {
            "affiliation": "Beth Israel Deaconess Medical Center", 
            "last_name": "Jeffrey Zwicker, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "AUC, Tmax, Cmax, elimination half-life over 24 hours (8 time points)", 
            "measure": "Pharmacokinetics profile", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01722669"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Dana-Farber Cancer Institute", 
            "investigator_full_name": "Jeffrey Zwicker, MD", 
            "investigator_title": "Assistant Professor, Harvard Medical School", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Measurement of protein disulfide inhibition in plasma using a fluorescent PDI substrate (dieosin glutathione disulfide)", 
                "measure": "pharmacokinetic inhibition of PDI", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Will evaluate inhibition of thrombin generation at 4 hours", 
                "measure": "Thrombin generation", 
                "safety_issue": "No", 
                "time_frame": "4 hours"
            }
        ], 
        "source": "Dana-Farber Cancer Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beth Israel Deaconess Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}